Seattle Genetics to Introduce More Drugs and increase its Employees

Clay Siegall is known to many as the co- founder of a biotechnology company known as Seattle Genetics. At the moment, he is the chairman of institutions board of directors and also the Chief Executive Officer. The company was started in the year 1998, and it has been dedicated to developing drugs for treating people with cancer and other important therapies.

Before starting Seattle Genetics, Clay Siegall was a part of an institution known as the Bristol-Myers Pharmaceutical Research Institute. He made several achievements in this company before going to the National Cancer Institute. Working in these biotechnology firms gave him the experience he needed to start his company.

Not long ago, Mirna Therapeutics, one of the respected biotech enterprises in the country announced that it had appointed Siegall to work as a member of its board of directors. According to a report from the company, Clay will serve as an outside director, and his input will be required in advancing better cancer treatments for cancer. Since Siegall is very knowledgeable in cancer treatments, he will help Mirna Therapeutics achieve its dreams. Siegall has a Ph.D. in Genetics which he acquired from one of the best educational institutions in the country.

Recently, Joe Biden, the Vice President of the United States visited the cancer research community in Seattle Genetics. This gesture from the government put the biotechnology company in the spotlight. The company has been recognized as one of the most successful and fastest growing biotechnology companies in the region.

Seattle Genetics announced during the vice president visit that it was planning to increase its drugs in the recent future. The company also announced its plans to increase its personnel to ensure that there is higher productivity in the institution. In five years, the company wants to introduce more than twelve drugs in the market.

The first drug from Seattle Genetics is known as Adcetris, and it has been doing well since it was introduced in the market. The drug is being tested in several types of lymphomas, and the CEO of the company believes that people with cancer will benefit from it.

Leave a Reply

You must be logged in to post a comment.